Experts InSight podcast

Retina Clinical Trial Update 2026

29.10.2026
0:00
46:23
Spol 15 sekunder tilbage
Spol 15 sekunder frem

Retina is producing Phase 3 results faster than ever, but FDA approval doesn't necessarily convey how a drug will fit into practice. Dr. Ehsan Rahimy joins host Dr. Jay Sridhar to unpack recent and somewhat puzzling trial results involving tyrosine kinase inhibitors, IL-6 inhibition, and the Wnt signaling pathway. They then confront the harder problem: When every trial uses a different population, comparator, and dosing scheme—and none tests against today's second-generation anti-VEGF agents—real-world practice is often shaped by anecdote rather than evidence.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Flere episoder fra "Experts InSight"